Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion
Ezekowitz, Michael D., MD, PhD, Cappato, Riccardo, MD, Klein, Allan L., MD, Camm, A. John, MD, Ma, Chang-Sheng, MD, Le Heuzey, Jean-Yves, MD, Talajic, Mario, MD, Scanavacca, Maurício I., MD, PhD, Vardas, Panos E., MD, Kirchhof, Paulus, MD, Hohnloser, Stefan H., MD, Hemmrich, Melanie, MD, Lanius, Vivian, PhD, Meng, Isabelle Ling, MD, PhD, Wildgoose, Peter, van Eickels, Martin, MD
Published in The American heart journal (01.05.2014)
Published in The American heart journal (01.05.2014)
Get full text
Journal Article
Trial design: Rivaroxaban for the prevention of major cardiovascular events post transcatheter aortic valve replacement: rationale and design of the GALILEO study
Windecker, Stephan, MD, Tijssen, Jan, PhD, Giustino, Gennaro, MD, Guimarães, Ana H.C., PhD, Mehran, Roxana, MD, Valgimigli, Marco, MD, PhD, Vranckx, Pascal, MD, PhD, Welsh, Robert C., MD, Baber, Usman, MD, van Es, Gerrit-Anne, PhD, Wildgoose, Peter, PhD, Volkl, Albert A., PharmD BCPS, Zazula, Ana, MD, Thomitzek, Karen, MD, Hemmrich, Melanie, MD, Dangas, George D., MD,PhD
Published in The American heart journal (2016)
Published in The American heart journal (2016)
Get full text
Journal Article